IP Library Granted Patent US 11,827,626
Granted Patent B2
US 11,827,626 · App. 17/401,642 · Granted Nov 28, 2023

Quinolines that modulate SERCA and their use for treating disease

Inventor: Russell Dahl (Saint John, IN)
Assignee: NEURODON CORPORATION
C07D405/12C07D215/40C07D409/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,827,626
App. No.
17/401,642
Granted
Nov 28, 2023
Kind
B2
Abstract

Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

Claims (15)

1. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, wherein the compound is selected from:

wherein the pharmaceutical composition is a solid form.

2. The pharmaceutical composition of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

3. The pharmaceutical composition of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

4. The pharmaceutical composition of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

5. A method for treating one or more symptoms of diabetes in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1 .

6. A method for treating one or more symptoms of diabetes in a subject in need thereof comprising administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

7. The method of claim 5 , wherein the compound is

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

8. The method of claim 5 , wherein the compound is

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2021
From: DAHL, RUSSELL
To: NEURODON CORPORATION
Reel/Frame 057193/0350 →
Continuity (5)
Continuation 16932832 · Jul 20, 2020
Continuation In Part 16258060 · Jan 25, 2019
Continuation In Part 15507228
Provisional Application 62044052 · Aug 29, 2014
Related Publication 20220048898A1 · Feb 17, 2022